Synthetic Oligonucleotides Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Synthetic oligonucleotides are moving from research tools towards medicines. This report estimates the global synthetic oligonucleotide market at $4,380 million in 2026, growing 13.1% a year to $8,100 million in 2031 and adding $3,720 million of new annual spending. Therapeutics grows 16.8% a year and overtakes Research as the largest application, custom oligos rise to 69.5% of the market, RNA oligos grow fastest by category and oligos longer than 100 bases grow fastest by length. The figures are manufacturer revenues for oligos, synthesis instruments, nucleosides and phosphoramidites and other reagents, not sales of finished drugs.

The past year brought FDA approval of Ionis's Tryngolza for severe hypertriglyceridemia and Arrowhead's Redemplo, fast growth in Alnylam's Amvuttra, Novartis's $12 billion purchase of Avidity Biosciences, rapid capacity growth at WuXi TIDES, Bachem, Agilent and ST Pharm, the enactment of the BIOSECURE Act, record results at Twist Bioscience, and new funding and deals in enzymatic synthesis and DNA data storage. The report covers 23 chapters, 58 tables and 46 figures, with forecasts by oligo length, application, product, category and type for 14 countries and regions, and profiles of 34 companies.

Get our research team working for you by ordering this comprehensive report. Your credit card order sends the report to your inbox instantly. Check all your licensing options but don't worry, your order is available as a credit if you wish to upgrade to more information.

Product Code: GENSYN 1026

List of Tables

List of Figures

1. Executive Summary

1.1 Situation Analysis
1.2 Market Snapshot
1.3 Key Findings
1.4 Investment & Strategic Thesis

2. Research Methodology & Scope

2.1 Scope & Market Definition
2.2 Value Basis
2.3 Market Segments
2.4 Geographic Coverage
2.5 Methodology
2.6 Sources
2.7 Author
2.8 Limitations

3. Introduction to Synthetic Oligonucleotides

3.1 What an Oligonucleotide Is
3.2 Phosphoramidite Chemistry and the Synthesis Cycle
3.3 Length, Coupling Efficiency and Yield
3.4 DNA, RNA and Chemical Modifications
3.5 Enzymatic Synthesis
3.6 History and the Industry Today

4. The Global Market for Synthetic Oligonucleotides

4.1 Global Market Overview by Country
4.2 Global Market by Oligo Length - Overview
4.3 Global Market by Application - Overview
4.4 Global Market by Product - Overview
4.5 Global Market by Category - Overview
4.6 Global Market by Type - Overview

5. Research & Diagnostic Oligonucleotides

5.1 The Research and Diagnostic Oligo Business
5.2 Primers and Probes
5.3 NGS Adapters, Oligo Pools and Hybrid-Capture Panels
5.4 CRISPR Guide RNAs for Research
5.5 PCR Diagnostics after COVID-19
5.6 Standard versus Custom, and Pricing

6. Oligonucleotide Therapeutics & CDMO Manufacturing

6.1 Therapeutic Oligonucleotides and How They Work
6.2 Approvals and the Shift to Prevalent Diseases
6.3 Why Volume Changes the Economics
6.4 The CDMO Landscape
6.5 Capacity, Scale and New Process Technologies
6.6 Outlook

7. Gene Synthesis, Long DNA & Enzymatic DNA Synthesis

7.1 Why Long DNA Is the Fastest-Growing Part of the Market
7.2 How Genes Are Made from Oligos
7.3 The Main Gene Synthesis Suppliers
7.4 Enzymatic DNA Synthesis
7.5 Benchtop Printers and Biosecurity
7.6 Outlook for Long and Enzymatic DNA

8. Raw Materials: Nucleosides, Phosphoramidites & Reagents

8.1 What Goes into an Oligonucleotide
8.2 Market Size and Drivers
8.3 The Main Suppliers
8.4 Solvents, Supports and Ancillary Reagents
8.5 Supply Security and Quality

9. Instruments, Automation & DNA Data Storage

9.1 The Instruments Market
9.2 Research and High-throughput Synthesizers
9.3 Process-scale Synthesis for Therapeutics
9.4 Array Synthesis and Semiconductor Platforms
9.5 DNA Data Storage
9.6 Outlook

10. Regulation, Biosecurity & Policy

10.1 An Industry Shaped by Several Rulebooks
10.2 Biosecurity: Screening of Synthetic DNA Orders
10.3 BIOSECURE and US-China Policy
10.4 GMP and Agency Expectations for Oligonucleotide Drug Substance
10.5 Impurities and Analytical Expectations
10.6 Diagnostics Rules, Export Controls and Trade

11. China & Asia-Pacific

11.1 Asia-Pacific in the Global Market
11.2 China
11.3 Japan
11.4 South Korea
11.5 India, Singapore and the Rest of Asia-Pacific
11.6 Outlook for the Region

12. Recent Developments

12.1 Alnylam’s Amvuttra Doubles but 2026 Guidance Is Trimmed
12.2 Novartis Completes Its Acquisition of Avidity Biosciences
12.3 BIOSECURE Act Becomes Law as WuXi AppTec Fights Its Listing
12.4 FDA Approves Tryngolza for Severe Hypertriglyceridemia
12.5 Twist Bioscience Reports Record Fiscal Third Quarter
12.6 Agilent Adds a Boulder Lab for Enzymatic Ligation
12.7 WuXi TIDES Revenue Grows 44% in the First Half
12.8 Bachem Confirms Strong 2026 and Heavy Investment
12.9 FDA Approves Arrowhead’s Redemplo, Its First Commercial siRNA
12.10 Ansa Biotechnologies Raises $54.4 Million Series B

13. Operations, Quality & Supply Chain

13.1 Synthesis Scale: From Nanomoles to Moles
13.2 Yield, Purity and Purification
13.3 Quality Control, Analytics and Turnaround
13.4 Raw Materials and Supply Chain
13.5 Solvent Use and Sustainability
13.6 Capacity and Utilisation

14. Competitive Landscape

14.1 Structure of Competition
14.2 Tiers of Players
14.3 Leading Players by Role
14.4 Consolidation and Notable Acquisitions
14.5 Competitive Dynamics
14.6 Outlook for Competition

15. SWOT, Porter's Five Forces & Investment Risk Analysis

15.1 SWOT Analysis
15.2 Porter's Five Forces
15.3 Investment Risk Analysis

16. Strategic Recommendations

16.1 Guidance for Executives, Marketing, Sales and Business Development
16.2 Guidance for Management Consultants and Investment Advisors

17. Market Forecast by Oligo Length, 2026-2031

17.1 ≤20-mer
17.2 21-50-mer
17.3 51-100-mer
17.4 >100-mer

18. Market Forecast by Application, 2026-2031

18.1 Research
18.2 Diagnostics
18.3 Therapeutics
18.4 Data Storage & Other

19. Market Forecast by Product, 2026-2031

19.1 Oligonucleotides
19.2 Instruments
19.3 Nucleosides & Phosphoramidites
19.4 Other Reagents

20. Market Forecast by Category, 2026-2031

20.1 Primers
20.2 Probes
20.3 DNA
20.4 RNA
20.5 Other Nucleic Acids

21. Market Forecast by Type, 2026-2031

21.1 Standard
21.2 Custom

22. Company Profiles

22.1 Agilent Technologies (Nucleic Acid Solutions Division)
22.2 Ajinomoto Bio-Pharma Services
22.3 Alnylam Pharmaceuticals
22.4 Ansa Biotechnologies
22.5 Arrowhead Pharmaceuticals
22.6 Asymchem Laboratories
22.7 Atlas Data Storage
22.8 Bachem
22.9 Biolytic Lab Performance
22.10 Biomemory
22.11 Bioneer Corporation
22.12 BioSpring
22.13 ChemGenes Corporation
22.14 CordenPharma
22.15 Cytiva (Danaher)
22.16 DNA Script
22.17 Elegen
22.18 Eurofins Genomics (Eurofins Scientific)
22.19 Eurogentec (Kaneka)
22.20 Evonetix
22.21 GenScript Biotech
22.22 Hongene Biotech
22.23 Integrated DNA Technologies (Danaher)
22.24 Ionis Pharmaceuticals
22.25 K&A Laborgerate
22.26 LGC Biosearch Technologies
22.27 Merck KGaA (MilliporeSigma)
22.28 Molecular Assemblies (Maravai LifeSciences)
22.29 Nitto Avecia (Nitto Denko)
22.30 Novartis (including Avidity Biosciences)
22.31 ST Pharm
22.32 Thermo Fisher Scientific
22.33 Twist Bioscience
22.34 WuXi STA / WuXi TIDES (WuXi AppTec)

23. Appendix

23.1 Abbreviations
23.2 Developments Archive
23.3 Report Limitations Restated

Product Code: GENSYN 1026

List of Tables

Table 1 Key Market Indicators (constant 2026 US$)
Table 2 Global Market by Segment, 2026 and 2031 (US$ millions, constant 2026 dollars)
Table 3 What This Report Counts
Table 4 The Phosphoramidite Synthesis Cycle
Table 5 Theoretical Full-Length Yield by Oligo Length and Coupling Efficiency
Table 6 Common Oligonucleotide Modifications
Table 7 Milestones in Oligonucleotide Synthesis
Table 8 Global Market by Country
Table 9 Global Market by Oligo Length
Table 10 Global Market by Application
Table 11 Global Market by Product
Table 12 Global Market by Category
Table 13 Global Market by Type
Table 14 Main Research and Diagnostic Oligonucleotide Products
Table 15 What Drives the Price of a Research or Diagnostic Oligo
Table 16 Main Classes of Therapeutic Oligonucleotides
Table 17 Leading Oligonucleotide CDMOs
Table 18 Synthetic Oligonucleotides Market by Oligo Length, 2026 and 2031
Table 19 Selected Gene Synthesis and Long DNA Suppliers, October 2026
Table 20 Synthetic Oligonucleotides Market by Product, 2026 and 2031
Table 21 Selected Suppliers of Nucleosides, Phosphoramidites and Reagents, October 2026
Table 22 Selected Oligonucleotide Synthesizer Suppliers, October 2026
Table 23 Selected DNA Data Storage Companies, October 2026
Table 24 Main Regulatory and Policy Instruments Affecting Synthetic Oligonucleotides
Table 25 Synthetic Oligonucleotides Market in Asia-Pacific, 2026 and 2031
Table 26 Selected Asia-Pacific Oligonucleotide Suppliers
Table 27 Recent Developments at a Glance
Table 28 Scales of Oligonucleotide Manufacture
Table 29 Typical Turnaround Times by Product Type
Table 30 Competitive Structure by Application
Table 31 Tiers of Synthetic Oligonucleotide Competitors
Table 32 Leading Therapeutic Oligonucleotide CDMOs
Table 33 Notable Acquisitions in Oligonucleotides, 2021-2026
Table 34 SWOT Analysis - Strengths and Weaknesses
Table 35 SWOT Analysis - Opportunities and Threats
Table 36 Porter's Five Forces Ratings
Table 37 Investment Risk Matrix
Table 38 Selected Growth Opportunities
Table 39 ≤20-mer by Country
Table 40 21-50-mer by Country
Table 41 51-100-mer by Country
Table 42 >100-mer by Country
Table 43 Research by Country
Table 44 Diagnostics by Country
Table 45 Therapeutics by Country
Table 46 Data Storage & Other by Country
Table 47 Oligonucleotides by Country
Table 48 Instruments by Country
Table 49 Nucleosides & Phosphoramidites by Country
Table 50 Other Reagents by Country
Table 51 Primers by Country
Table 52 Probes by Country
Table 53 DNA by Country
Table 54 RNA by Country
Table 55 Other Nucleic Acids by Country
Table 56 Standard by Country
Table 57 Custom by Country
Table 58 Developments Archive: Items in the Previous Edition

List of Figures

Figure 1 Key Graphic - Medicines Overtake Research: Synthetic Oligonucleotides Market by Application, 2026 vs 2031
Figure 2 Global Market Pareto Chart
Figure 3 Global Market by Oligo Length - Base vs. Final
Figure 4 Global Market by Oligo Length Base Year
Figure 5 Global Market by Oligo Length End Year
Figure 6 Oligo Length Share by Year
Figure 7 Oligo Length Segments Growth
Figure 8 Global Market by Application - Base vs. Final
Figure 9 Global Market by Application Base Year
Figure 10 Global Market by Application End Year
Figure 11 Application Share by Year
Figure 12 Application Segments Growth
Figure 13 Global Market by Product - Base vs. Final
Figure 14 Global Market by Product Base Year
Figure 15 Global Market by Product End Year
Figure 16 Product Share by Year
Figure 17 Product Segments Growth
Figure 18 Global Market by Category - Base vs. Final
Figure 19 Global Market by Category Base Year
Figure 20 Global Market by Category End Year
Figure 21 Category Share by Year
Figure 22 Category Segments Growth
Figure 23 Global Market by Type - Base vs. Final
Figure 24 Global Market by Type Base Year
Figure 25 Global Market by Type End Year
Figure 26 Type Share by Year
Figure 27 Type Segments Growth
Figure 28 ≤20-mer Growth
Figure 29 21-50-mer Growth
Figure 30 51-100-mer Growth
Figure 31 >100-mer Growth
Figure 32 Research Growth
Figure 33 Diagnostics Growth
Figure 34 Therapeutics Growth
Figure 35 Data Storage & Other Growth
Figure 36 Oligonucleotides Growth
Figure 37 Instruments Growth
Figure 38 Nucleosides & Phosphoramidites Growth
Figure 39 Other Reagents Growth
Figure 40 Primers Growth
Figure 41 Probes Growth
Figure 42 DNA Growth
Figure 43 RNA Growth
Figure 44 Other Nucleic Acids Growth
Figure 45 Standard Growth
Figure 46 Custom Growth

Synthetic Oligonucleotides Markets: Market Forecast, Competitive Landscape, Technology and Policy Outlook, 2027-2031

Description

Table of Contents

List of Tables

Report Overview:

Table of Contents

List of Tables

List of Figures

1. Executive Summary

2. Research Methodology & Scope

3. Introduction to Synthetic Oligonucleotides

4. The Global Market for Synthetic Oligonucleotides

5. Research & Diagnostic Oligonucleotides

6. Oligonucleotide Therapeutics & CDMO Manufacturing

7. Gene Synthesis, Long DNA & Enzymatic DNA Synthesis

8. Raw Materials: Nucleosides, Phosphoramidites & Reagents

9. Instruments, Automation & DNA Data Storage

10. Regulation, Biosecurity & Policy

11. China & Asia-Pacific

12. Recent Developments

13. Operations, Quality & Supply Chain

14. Competitive Landscape

15. SWOT, Porter's Five Forces & Investment Risk Analysis

16. Strategic Recommendations

17. Market Forecast by Oligo Length, 2026-2031

18. Market Forecast by Application, 2026-2031

19. Market Forecast by Product, 2026-2031

20. Market Forecast by Category, 2026-2031

21. Market Forecast by Type, 2026-2031

22. Company Profiles

23. Appendix

List of Tables

List of Figures